939412-86-9

Basic information

• Product Name: (3-Chloropyrazin-2-yl)MethanaMine hydrochloride
• Synonyms: 3-Chloro-2-pyrazinemethanamine hydrochloride;2-Pyrazinemethanamine, 3-chloro-, hydrochloride (1:1);QC-6916;3-Chloropyrazine-2-yl-methylamine hydrochloride
• CAS NO: 939412-86-9
• Molecular Formula: C₅H₆ClN₃*ClH
• Molecular Weight: 180.03518
• Mol File: 939412-86-9.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: (3-Chloropyrazin-2-yl)MethanaMine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: (3-Chloropyrazin-2-yl)MethanaMine hydrochloride(939412-86-9)
• EPA Substance Registry System: (3-Chloropyrazin-2-yl)MethanaMine hydrochloride(939412-86-9)

Safety Data

• Hazardous Substances Data: 939412-86-9(Hazardous Substances Data)

Usage

General Description

(3-Chloropyrazin-2-yl)MethanaMine hydrochloride is a chemical compound that consists of a chlorine-substituted pyrazine compound and a methanamine molecule attached to a hydrochloride salt. It is commonly used in organic synthesis as a building block for various pharmaceutical and agrochemical products. (3-Chloropyrazin-2-yl)MethanaMine hydrochloride can be utilized in the preparation of diverse chemical structures and can serve as a valuable intermediate in the production of functional materials. Additionally, it may have potential applications in the development of new drugs and research in the fields of medicinal chemistry and chemical biology.

Upstream product

• 55557-52-3 2-chloro-3-cyanopyrazine 
• 939412-89-2 N-(3-chloro-pyrazin-2-ylmethyl)-N-formyl-formamide 
• 939412-88-1 1-(3-chloro-pyrazin-2-ylmethyl)-3,5,7-triaza-1-azonia-tricyclo[3.3.1.1*3,7*]decane; chloride 
• 867165-55-7 2-((3-chloropyrazin-2-yl)methyl)isoindoline-1,3-dione 

Downstream Products

• 939412-84-7 N-[(2-chlorophenyl(methyl))]-3-oxocyclobutanecarboxamide 
• 1620676-25-6 (2R,5R)-tert-butyl 5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-(((3-chloropyrazin-2-yl)methyl)carbamoyl)morpholine-4-carboxylate 
• 1419222-52-8 (2S,5R)-benzyl 5-(((3-chloropyrazin-2-yl)methyl)carbamoyl)-2-(hydroxymethyl)piperidine-1-carboxylate 
• 1620676-74-5 benzyl 4-(((3-chloropyrazin-2-yl)methyl)carbamoyl)-2-cyanopiperidine-1-carboxylate 
• 1418307-17-1 benzyl (S)-2-(((3-chloropyrazin-2-yl)methyl)carbamoyl)pyrrolidine-1-carboxylate 
• 1418307-23-9 benzyl (2S)-2-([(3-chloropyrazin-2-yl)methyl]carbamoyl)piperidine-1-carboxylate 
• 1419221-77-4 benzyl (3R)-3-([(3-chloropyrazin-2-yl)methyl]carbamoyl)piperidine-1-carboxylate 
• 936901-76-7 benzyl[(trans-4-{[(3-chloropyrazin-2-yl)methyl]carbamoyl}cyclohexyl)methyl]carbamate 
• 1326281-48-4 benzyl-3-(((3-chloropyrazin-2-yl)methyl)carbamoyl)azetidine-1-carboxylate 
• 1326280-86-7 (trans)-N-((3-chloropyrazin-2-yl)methyl)-4-hydroxycyclohexanecarboxamide 
• 1326283-22-0 (cis)-N-((3-chloropyrazin-2-yl)methyl)-4-hydroxycyclohexanecarboxamide 
• 1326280-45-8 N-((3-chloropyrazin-2-yl)methyl)-4-oxocyclohexane-1-carboxamide 
• 1326282-06-7 benzyl 4-((3-chloropyrazin-2-yl)methylcarbamoyl)piperazine-1-carboxylate 
• 1300022-29-0 N-(3-chloro-pyrazin-2-ylmethyl)-4-fluoro-benzamide 

Relevant articles and documents

Preparation method capable of acalabrutinib being used for treating leukemia

The invention relates to a preparation method of acalabrutinib capable of being used for treating leukemia. The synthesis method of the compound 3 is optimized, so that according to the method, the cyano compound 2 is reduced to obtain the compound 3 by adopting a method of generating borane in situ under the conditions of indium trichloride and sodium borohydride. The method is simple and convenient to operate, a special reaction container and hydrogen are not needed for reduction, a high-risk catalyst nickel is prevented from being adopted, and large-scale production is facilitated; in the preparation of the compound 8, under the condition of a catalyst, large-scale preparation is realized by adding an ammonia water closed system, so that a method of introducing ammonia gas at an extremely low temperature is avoided, and large-scale production is facilitated.

Imidazopyrazines as Selective BTK Inhibitors

The invention relates to imidazopyrazine compounds as selective Bruton's tyrosine kinase (BTK) inhibitors. In particular, the invention discloses (S)-4-(8-amino-3-(1-(butyl-2-acetylenyl) pyrrolidine-2-yl) imidazo [1, 5-a] pyrazine-1-yl)-N-(pyridine-2-yl) benzamide and a deuterated compound of an optical isomer thereof, or a pharmaceutically acceptable salt or to a pharmaceutical composition containing the compound, and use thereof in the treatment of BTK-mediated diseases.

HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF

Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated modulate the NMDA receptor.